Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
1998-06-29
2001-04-03
Goldberg, Jerome D. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
06211239
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the use of a retinoid having unique properties for the treatment or prevention of breast cancer or leukemia. More specifically, the present invention relates to the use of 6-[3-[1adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN) to treat or prevent breast cancer or leukemia.
BACKGROUND OF THE INVENTION
Retinoids are defined as substances that can elicit specific biological responses by binding to and activating a specific receptor or set of receptors. Retinoids are known to play a fundamental role in normal cell growth and differentiation. (Roberts, A. B. et al, in “The Retinoids,” ed. by M. B. Sporn, A. B. Roberts and D. S. Goodman, Vol. 2, pp. 209-256, Academic Press, Orlando, Fla., (1984); Sporn, M. B. et al,
J. Amer. Acad. Dermatol.,
15:756-764 (1986)). Multiple retinoic acid nuclear receptors. (RAR&agr;, &bgr; and &ggr;) and retinoid X receptors (RXR&agr;, &bgr; and &ggr;) have been identified (Evans, R. M.,
Science,
240:889-895 (1988); O'Malley, B. W.,
Mol. Endocrin.,
4:363-364 (1990); Gudas, L. J.
Cell Growth Differ,
3:655-662 (1992)); Lohnes et al,
Cell Sci.,
16 (Suppl): 69-76 (1992). Moreover, numerous isoforms of the various nuclear receptors exist as a result of alternative splicing (Gudas L. J.,
J. Biol. Chem.,
269:15399-15402 (1994)).
Retinoic acid receptors mediate gene transcription through a variety of mechanisms. These nuclear receptors can bind to specific DNA consensus sequences termed retinoid receptor response elements (RAREs or RXREs) which are located in the regulatory regions of the retinoid target genes (Gudas, L. J.,
Cell Growth Differ.,
3:655-662 (1992); Lohnes et al,
Cell Sci.,
16 (Suppl.):69-76 (1992)). Nuclear receptor binding to these response elements preferably occurs through heterodimer formation between the RAR and RXR, although homodimer binding and subsequent gene activation has also been found (Hermann et al,
Mol. Endocrinol.,
6:1153-1162 (1992); Leid et al,
Cell,
68:377-395 (1992); Zhang X,
Nature,
355:441-446 (1992)). The RXRs can mediate gene transcription via heterodimer formation with the RARs, with the vitamin D, thyroid hormone (Yu et al,
Cell,
67:1251-1266 (1991); Hermann et al,
Mol. Endocrinol.,
6:1153-1162 (1992); Kliewer et al,
Nature,
355:446-449 (1992); Leid et al,
Cell,
68:377-395 (1992); Zhang et al,
Nature,
355:441-446 (1992)), and a number of orphan receptors. (Apfel et al,
Mol. Cell Biol.,
14:7025-7035 (1994); Song et al,
Proc. Natl. Acad. Sci., USA
91:10809-10813 (1994)). These orphan receptors can, in turn, inhibit the activity of RARs and thyroid nuclear receptors (TRs) (Kliewer et al,
Proc. Natl. Acad. Sci., USA,
89:1448-1452 (1992); Tran et al,
Mol. Cell Biol.,
12:4666-4676 (1992); Apfel et al,
Mol. Cell Biol.,
14:7025-7035 (1994), Casanova et al,
Mol. Cell Biol.,
14:5756-5765 (1991); Song et al,
Proc. Natl. Acad. Sci., USA,
91:10809-10813 (1994)).
The retinoid receptor response elements usually consist of direct repeats (DRs) in which the half-sites are separated by a number of base pair spacers. Selectivity for binding appears to be determined by the number of base pairs utilized as spacers, as well as by the sequence of the response element itself (Kim et al,
Mol. Endocrinol.,
6:1489-1501 (1992), Mader et al,
J. Biol. Chem.,
268:591-600 (1993)).
RAR and RXR inhibition of AP-1-mediated gene transcription that does not require RAR or RXR binding to DNA has also been observed (Pfahl,
Endocrin. Reviews,
14:651-658 (1993), and references cited therein); RAR and RXR when completed to their ligands have been shown to inhibit c-Jun/c-Fos binding to the AP-1 consensus sequence and subsequent gene activation (Pfahl,
Endocrine Reviews,
14:651-658 (1993), and references cited therein). Negative regulation of transcription by RA can apparently also occur by means that do not involve RAR binding to the promoter region but by inhibiting enhancer activity (Gudas,
J. Biol. Chem.,
269:15399-15402 (1994)). In addition, negative regulation of RAR-mediated, as well as TR-mediated, gene transcription occurs by the competitive binding of the orphan receptor coup and v-ErbA to RARE and TREs (Tran et al,
Mol. Cell. Biol.,
12:4666-4676 (1992), Hermann et al,
Oncogene,
8:55-65 (1993)).
Most cell types express more than one RAR and RXR receptor. RAR homologous recombination studies have suggested that RAR functional redundancy exists among the different RARs (Li et al,
Proc. Natl. Acad. Sci., USA,
90:1590-1594 (1993), Lohnes et al,
Cell,
73: 643-658 (1993), Lufkin et al,
Proc. Natl. Acad. Sci., USA,
90:7225-7229 (1993)). However, other studies have indicated that the various receptor subtypes possess distinct functions and may indeed modulate the activity of distinct genes (Nagpal et al,
Cell,
70:1007-1019 (1992); Boylan et al,
Mol. Cell Biol.,
15:843-851 (1995)). Evidence also suggests a unique role for each of the receptor subtypes: (1) receptor selectivity towards specific transactivating response elements has been demonstrated (Nagpal et al,
Cell,
70:1007-1019 (1992)); and (2) specific cell types have become refractory to the antiproliferative and differentiating effects of RA with the loss of one receptor subtype, despite the presence of other RAR subtypes (Sheikh et al,
J. Cell Biochem.,
53:393-403 (1993); Moasser et al,
Oncogene,
9:833-840 (1994)).
The RARs bind both RA and its isomer 9-cis-RA, while the RXRs only bind 9-cis-RA (Allenby et al,
J. Biol. Chem.,
269:16689-16695 (1995), and references cited therein). To further document a unique function for each receptor subtype, conformationally restricted retinoids have been synthesized that selectively bind to and enhance transcriptional activation by selective RAR and RXR subtypes (Graupner et al,
Biochem. Biophys. Res. Commun.,
179:1554-1561 (1991); Lehmann et al,
Cancer Res.,
61:4804-4809 (1991), Lehmann et al,
Science,
258:1944-1946 (1992); Dawson et al, in “Retinoids: New Treatments in Research and Clinical Applications”. Livrea M A and Packer L., (eds) Marcel Dekker: NY pp 205-221 (1992); Davies et al,
Amer. Ass'n of Cancer Res. Conf.,
Banff, Alberta, Canada, Mar. 15-20 (1993) Abst. B-28; Jong et al,
J. Med. Chem.,
36:2605-2613 (1993); Reichert et al, from “Mol. Biol. to Therapeutics: Pharmacology of the Skin”, Vol. 5, Bernard B A and Shroot B (eds), Karger: B.2d pp 117-127 (1993); Beard et al,
Bioorg. Med. Chemical,
4:1447-1452 (1994); and Boehm et al,
J. Med. Chem.,
37:2936-2941 (1994)).
These synthetic receptor-selective retinoids have further confirmed the uniqueness of specific RAR sub-types in modulating RA responses in various cell types (Rudd et al,
Cancer Letter,
73:41-49 (1993); Sheikh et al,
J. Biol. Chem.,
269:21440-21447 (1994)). Recently, a series of synthetic retinoids has been described that selectively transactivate RAR&ggr; (Bernard et al,
Biochem. Biophys. Res. Comm.,
186(2):977-983 (1992)).
Because of the ability of retinoids to affect cell growth and differentiation, these compounds have been disclosed to be useful for the treatment or prevention of diseases and conditions involving abnormal cell proliferation and differentiation. For example, the usage of retinoids as efficient therapeutics for the treatment of various skin diseases and neoplasms has been reported (Roberts, A. B. and Sporn, M. B., in “The Retinoids”, Sporn et al, pp 209-286, Academic Press, Orlando, Fla; Bollag et al,
Ann. Oncol.,
3:513-526 (1992); Smith et al,
J. Clin. Oncol.,
10:839-864 (1992)).
To date, the best results of retinoid therapy have typically been achieved with a regimen which combines retinoid administration with the administration of other differentiation or cytotoxic agents. Besides retinol and retinoic acid, isotretoin (13-cis-retinoic acid) and etretinate have been used, as well as 9-cis retinoic acid and N-(9-hydroxyphenyl)retinoid.
The most convincing results have been documented in the field of dermological disorders, where topical application can circumvent the toxic
Burns Doane Swecker & Mathis L.L.P.
Centre International de Recherches Dermatologiques Galderma
Goldberg Jerome D.
LandOfFree
Method for treating or preventing breast cancer or leukemia... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating or preventing breast cancer or leukemia..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating or preventing breast cancer or leukemia... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2479846